

PsA Patients choose to stay with Stelara For the long runs⁵



More patients remain on treatment with Stelara[®] than with anti-TNFα after one prior anti-TNFα failure⁵.



Stelara[®] achieves significant long-term improvements in QoL, including improvements in pain and mental health⁶⁻⁸

SEE THE EVIDENCE



Supporting you and your patients in the treatment of autoimmune conditions since 2009⁴



Over the last 7 years, the estimated cumulative worldwide exposure to Stelara[®] is 777,478 patient-years^{**9}

PsA, Psoriatic Arthritis; QoL, quality of life.

Cumulative incidence of serious infections per 100 patient-years among patients in PSOLAR. Data are shown by treatment cohort in the overall, incident, and bio-naïve populations. Data shown is for psoriasis

patients, of which 35.7% reported having PsA and 14.2% reported having PsA diagnosis confirmed by a rheumatologist.

†The overall population includes patients who received a biologic agent before (prevalent population) or after (incident population) enrolling in the registry.

‡The incident population, a subset of the overall population, includes patients who received a biologic agent

at or after enrolling in the registry but may have been exposed to a different biologic previously.

The bio-naïve population is a further subset of the incident population and includes patients who received

their first biologic agent at or after enrolling in the registry and have never received prior biologic exposure.

The other biologics cohort includes patients who received alefacept, efalizumab, golimumab and other investigational biologic agents.

**From launch to 31 December 2016.

References

1. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Lancet 2013;382:780–789.
2. Kalb RE, Fiorentino DF, Lebwohl MG, et al. JAMA Dermatol 2015;151(9):961–969.
3. Papp K, Gottlieb AB, Naldi L, et al. J Drugs Dermatol 2015;14(7):706–714.
4. Stelara[®] 90 mg and 45 mg solution for injection. Summary of Product Characteristics, November 2016
5. Stelara[®] 90 mg and 45 mg solution for injection. Summary of Product Characteristics, November 2016
6. Kavanaugh A, Cush JJ, Ahmed MS, et al. Arthritis Care Res (Hoboken) 2015;67(12):1739–1749.
7. Kavanaugh A, Puig L, Gottlieb AB, et al. Ann Rheum Dis 2016;75(11):1984–1988.
8. Rahman P, Puig L, Gottlieb AB, et al. Arthritis Care Res (Hoboken) 2016;68(12):1812–1822.
9. Janssen Data on File. STE/DoF/Mar17/EMEA003.



SUSTAINED

EFFICACY

SAFETY

SATISFACTION